EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta …
CL Vale, D Fisher, A Kneebone, C Parker, M Pearse… - The Lancet, 2020 - thelancet.com
Background It is unclear whether adjuvant or early salvage radiotherapy following radical
prostatectomy is more appropriate for men who present with localised or locally advanced …
prostatectomy is more appropriate for men who present with localised or locally advanced …
The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an …
A Pollack, TG Karrison, AG Balogh, LG Gomella… - The Lancet, 2022 - thelancet.com
Background In men with a detectable prostate-specific antigen (PSA) level after
prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in …
prostatectomy for prostate cancer, salvage prostate bed radiotherapy (PBRT) results in …
Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non …
A Kneebone, C Fraser-Browne, GM Duchesne… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy has been shown to halve the risk of biochemical
progression for patients with high-risk disease after radical prostatectomy. Early salvage …
progression for patients with high-risk disease after radical prostatectomy. Early salvage …
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical …
P Sargos, S Chabaud, I Latorzeff, N Magné… - The Lancet …, 2020 - thelancet.com
Background Adjuvant radiotherapy reduces the risk of biochemical progression in prostate
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …
cancer patients after radical prostatectomy. We aimed to compare adjuvant versus early …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
[HTML][HTML] Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …
advances in imaging and molecular characterisation have resulted in multiple areas where …
Molecular biomarkers in localized prostate cancer: ASCO guideline
PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …
cancer biomarkers geared toward patient selection for active surveillance, identification of …
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
C Parker, S Gillessen, A Heidenreich… - Annals of …, 2015 - annalsofoncology.org
Subclinical prostate cancer is common in men> 50 years of age. Population-based
screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) …
screening of men aged between 55 and 69 years, using prostate-specific antigen (PSA) …